HC Wainwright & Co. Maintains Buy on Legend Biotech, Lowers Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Legend Biotech (NASDAQ:LEGN) but lowered the price target from $86 to $73.

May 24, 2024 | 10:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Legend Biotech but lowered the price target from $86 to $73. This indicates continued confidence in the company's prospects, albeit with a more conservative valuation.
The maintained Buy rating suggests that the analyst still sees potential in Legend Biotech, but the lowered price target reflects a more cautious outlook. This could lead to a neutral short-term impact on the stock price as investors digest the mixed signals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100